



**TTK Healthcare
LIMITED**

TTKHC:SEC:GJ:024:22

February 09, 2022

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra East
Mumbai 400 051

SCRIP CODE: 507747

SCRIP CODE: TTKHLTCARE

Dear Sirs,

**Re : Unaudited Financial Results along with Limited Review Report for the Third
Quarter ended 31st December, 2021**

We are forwarding herewith the Unaudited Financial Results along with the Limited Review Report from the Statutory Auditors of the Company, for the Third Quarter ended 31st December, 2021, duly reviewed by the Audit Committee at their meeting held yesterday (i.e.) on 8th February, 2022 and approved by the Board of Directors of the Company at their Meeting held today.

Kindly take the above documents on record.

Thanking you

Yours faithfully
For TTK Healthcare Limited

(S KALYANARAMAN)
Wholetime Director & Secretary

Encl. : a/a



TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND PERIOD ENDED 31ST DECEMBER, 2021

[Prepared in compliance with the Indian Accounting Standards (Ind AS)]

(Rs. in lakhs)

Sl. No.	Particulars	For the Quarter ended			For the period ended		For the year ended
		(31/12/2021)	(30/09/2021)	(31/12/2020)	(31/12/2021)	(31/12/2020)	(31/03/2021)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I.	Revenue from Operations	21,249.43	20,635.55	17,918.97	58,964.10	45,525.27	63,652.79
II.	Other Income	447.21	303.77	253.39	1,116.81	661.14	1,000.01
III.	Total Income (I + II)	21,696.64	20,939.32	18,172.36	60,080.91	46,186.41	64,652.80
IV.	Expenses						
	(a) Cost of materials consumed	3,872.00	3,564.68	2,701.73	10,028.63	6,978.28	9,891.54
	(b) Purchase of Stock-in-trade	5,868.62	4,496.42	4,379.77	14,646.03	10,149.68	14,876.91
	(c) Changes in inventories of Finished Goods, Work-in-progress and Stock-in-trade	(778.29)	262.09	(174.86)	(767.15)	695.45	405.32
	(d) Employee benefits expense	4,383.41	3,780.20	4,080.74	12,354.46	11,577.72	16,007.53
	(e) Finance Costs	148.60	55.43	35.29	266.55	156.59	222.38
	(f) Depreciation and Amortization Expense	332.36	326.09	336.74	993.00	1,033.46	1,371.13
	(g) Other Expenses	6,192.53	6,953.77	5,750.49	18,532.12	14,106.82	18,982.59
	Total Expenses (IV)	20,019.23	19,438.68	17,109.90	56,053.64	44,698.00	61,757.40
V.	Profit / (Loss) before Exceptional Items and Tax (III - IV)	1,677.41	1,500.64	1,062.46	4,027.27	1,488.41	2,895.40
VI.	Exceptional Items [Refer Note No.4 below]	-	249.05	-	249.05	809.79	809.79
VII.	Profit / (Loss) before Tax (V + VI)	1,677.41	1,749.69	1,062.46	4,276.32	2,298.20	3,705.19
VIII.	Tax Expense:						
	(1) Current Tax	490.00	500.00	340.00	1,270.00	760.00	1,225.00
	(2) Deferred Tax	(29.07)	(31.12)	(46.20)	(90.55)	(106.30)	(199.11)
	(3) Tax relating to earlier years [Refer Note No.4 below]	-	-	-	-	(1,964.81)	(1,964.81)
IX.	Profit / (Loss) for the period from Continuing Operations (VII-VIII)	1,216.48	1,280.81	768.66	3,096.87	3,609.31	4,644.11
X.	Profit / (Loss) from Discontinued Operations	-	-	-	-	-	-
XI.	Tax Expense of Discontinued Operations	-	-	-	-	-	-
XII.	Profit / (Loss) from Discontinued Operations (after tax) (X - XI)	-	-	-	-	-	-
XIII.	Profit / (Loss) for the period (IX + XII)	1,216.48	1,280.81	768.66	3,096.87	3,609.31	4,644.11
XIV.	Other Comprehensive Income:						
	(A) (i) Items that will not be reclassified subsequently to profit or loss	180.00	(78.49)	16.12	485.90	246.47	315.27
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(20.59)	8.97	(0.56)	(54.75)	2.35	29.88
	(B) (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV.	Total Comprehensive Income for the period (XIII + XIV) [Comprising Profit / (Loss) and Other Comprehensive Income for the period]	1,375.89	1,211.29	784.22	3,528.02	3,858.13	4,989.26
	Paid-up Equity Share Capital (Face Value Rs.10 per share)	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03
	Other Equity as per Balance Sheet of previous accounting year (excluding Revaluation Reserve)	-	-	-	-	-	27,610.18

		(Rs. in lakhs)					
Sl. No.	Particulars	For the Quarter ended			For the period ended		For the year ended
		(31/12/2021)	(30/09/2021)	(31/12/2020)	(31/12/2021)	(31/12/2020)	(31/03/2021)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
XVI.	Earnings per Equity Share (For Continuing Operations):						
(1)	Basic (in Rs.)	8.61	9.07	5.44	21.92	25.54	32.87
(2)	Diluted (in Rs.)	8.61	9.07	5.44	21.92	25.54	32.87
XVII.	Earnings per Equity Share (For Discontinued Operations):						
(1)	Basic (in Rs.)	-	-	-	-	-	-
(2)	Diluted (in Rs.)	-	-	-	-	-	-
XVIII.	Earnings per Equity Share (For Continuing and Discontinued Operations):						
(1)	Basic (in Rs.)	8.61	9.07	5.44	21.92	25.54	32.87
(2)	Diluted (in Rs.)	8.61	9.07	5.44	21.92	25.54	32.87

Notes:

- (1) The above financial results for the Third Quarter and Period ended 31st December, 2021 in respect of TTK Healthcare Limited (the Company) have been reviewed by the Audit Committee at its meeting held on 8th February, 2022 and approved by the Board of Directors of the Company at its meeting held on 9th February, 2022 through Video Conferencing.
- (2) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (3) The second wave of CoVID-19 and the extended lockdown during the First Quarter of the Financial year 2021-22 has marginally impacted the business of the Company. Considering the ongoing vaccination drive and other sustainable actions taken by the Management, both with reference to the environment and its employees' health, the impact has been minimal.
The Company, based on current estimates, expects that the carrying amount of all its assets will be recovered, net of provisions established. However, the impact assessment of CoVID-19 is a continuing process, given the uncertainties associated with its nature and duration. The Company will continue to monitor any material changes to future economic conditions.
- (4) (i) Exceptional Items relating to FY 2021-22: In September, 2021, the Company sold land admeasuring 4.595 acres held by it at Perungudi Village, Tirunelveli District, Tamilnadu on which the Company has earned a profit of Rs.249.05 lakhs.
(ii) Exceptional Items relating to FY 2020-21: The Company's claim in respect of tax benefits due to adjustment of unabsorbed losses and depreciation of the erstwhile TTK Protective Devices Limited and TSL Techno Services Limited which merged with the Company w.e.f. 1st April, 2012, (shown as Contingent Asset in earlier years), has been allowed. The Company has received the revised assessment orders in the previous FY 20-21 and the refund received is accounted as follows:
(a) Rs.809.79 lakhs towards Interest on Tax Refund received is treated as Exceptional Income; and
(b) Balance Refund received (net of provisions of Rs 999.74 lakhs considered necessary) of Rs.1,964.81 lakhs has been accounted as Tax Refund relating to earlier years.
- (5) Implementation of the Code of Social Security, 2020, which is likely to impact the contributions by the Company towards Provident Fund, Gratuity and other related areas has been deferred by the Government beyond 1st April, 2021. However, the Company based on the initial assessment made a provision for Rs.350 Lakhs in the Fourth Quarter of FY 20-21 and proposes to take further appropriate action after the Rules are made applicable.
- (6) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.
- (7) This Statement is also available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).

For TTK HEALTHCARE LIMITED



T T RAGHUNATHAN
Executive Vice Chairman

Place : Chennai
Date : February 09, 2022



TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

**SEGMENTWISE REVENUE, RESULTS, ASSETS & LIABILITIES FOR THE QUARTER AND PERIOD ENDED
31ST DECEMBER, 2021**

(Rs. in lakhs)

Sl. No.	Particulars	For the Quarter ended			For the period ended		For the year ended
		(31/12/2021)	(30/09/2021)	(31/12/2020)	(31/12/2021)	(31/12/2020)	(31/03/2021)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Segment Revenue: (Sales and Other Operating Income)						
(a)	Pharmaceuticals	8,044.72	8,128.70	6,918.08	22,345.28	17,467.27	23,844.31
(b)	Consumer Products	5,509.16	5,444.84	4,966.52	16,679.69	12,976.96	17,485.02
(c)	Medical Devices	1,522.36	1,405.27	650.94	3,500.97	1,381.64	2,673.24
(d)	Protective Devices	3,671.93	3,216.81	2,908.76	9,439.52	6,508.98	9,457.14
(e)	Foods	2,491.53	2,434.33	2,468.28	6,980.78	7,166.16	10,162.14
(f)	Others	9.73	5.60	6.39	17.86	24.26	30.94
	Total	21,249.43	20,635.55	17,918.97	58,964.10	45,525.27	63,652.79
	Less : Inter Segment Revenue	-	-	-	-	-	-
	Net Sales / Income from Operations	21,249.43	20,635.55	17,918.97	58,964.10	45,525.27	63,652.79
2.	Segment Results: [Profit (+) / Loss (-) before tax and interest from each segment]						
(a)	Pharmaceuticals	1,323.35	1,722.01	945.65	3,711.13	1,801.35	2,707.12
(b)	Consumer Products	518.77	318.06	506.54	1,552.19	1,864.42	2,026.89
(c)	Medical Devices	187.64	205.63	(165.53)	247.33	(685.79)	(535.21)
(d)	Protective Devices	(40.90)	(474.04)	(49.25)	(511.70)	(697.03)	(330.32)
(e)	Foods	(30.49)	(56.66)	45.78	(199.83)	(15.77)	103.47
(f)	Others	6.02	4.99	5.81	13.90	20.01	25.29
	Total	1,964.39	1,719.99	1,289.00	4,813.02	2,287.19	3,997.24
	Less : Finance Cost	148.60	55.43	35.29	266.55	156.59	222.38
	Less : Unallocable Expenses (Net of Unallocable Income)	138.38	(85.13)	191.25	270.15	(167.60)	69.67
	Total Profit (+) / Loss (-) before tax	1,677.41	1,749.69	1,062.46	4,276.32	2,298.20	3,705.19
		As on 31/12/2021	As on 30/09/2021	As on 31/12/2020	As on 31/12/2021	As on 31/12/2020	As on 31/03/2021
3.	Segment Assets						
(a)	Pharmaceuticals	6,743.90	6,893.59	6,428.89	6,743.90	6,428.89	5,579.36
(b)	Consumer Products	2,966.88	2,634.51	2,491.80	2,966.88	2,491.80	3,025.93
(c)	Medical Devices	4,596.37	4,172.72	3,706.71	4,596.37	3,706.71	3,660.51
(d)	Protective Devices	9,459.50	7,953.90	7,183.37	9,459.50	7,183.37	7,271.38
(e)	Foods	9,519.77	9,515.96	8,856.90	9,519.77	8,856.90	9,082.23
(f)	Others	185.89	179.49	169.14	185.89	169.14	173.72
	Total	33,472.31	31,350.17	28,836.81	33,472.31	28,836.81	28,793.13
	Unallocated	27,768.35	26,485.50	22,698.63	27,768.35	22,698.63	24,766.07
	Total Assets	61,240.66	57,835.67	51,535.44	61,240.66	51,535.44	53,559.20
4.	Segment Liabilities						
(a)	Pharmaceuticals	7,638.91	7,501.43	7,101.51	7,638.91	7,101.51	6,383.04
(b)	Consumer Products	6,926.12	7,436.43	5,897.24	6,926.12	5,897.24	6,589.60
(c)	Medical Devices	1,756.16	1,664.73	1,320.08	1,756.16	1,320.08	1,233.11
(d)	Protective Devices	3,783.18	3,166.93	2,046.37	3,783.18	2,046.37	2,088.98
(e)	Foods	1,497.11	1,631.57	1,664.57	1,497.11	1,664.57	1,582.31
(f)	Others	135.01	131.92	133.45	135.01	133.45	132.94
	Total	21,736.49	21,533.01	18,163.22	21,736.49	18,163.22	18,009.98
	Unallocated	7,359.26	5,533.72	5,038.70	7,359.26	5,038.70	6,084.59
	Total Liabilities	29,095.75	27,066.73	23,201.92	29,095.75	23,201.92	24,094.57

Notes:

1. Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (Ind AS 108) based on review of performance by the Top Management.
2. Details of products included in each of the Segments are as below :
 - ❖ Pharmaceuticals include products for both Human and Veterinary use.
 - ❖ Consumer Products comprise marketing and distribution of Woodward's Gripewater, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Freshners, etc.
 - ❖ Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc.
 - ❖ Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products.
 - ❖ Foods comprise manufacturing and marketing of Food Products.
 - ❖ "Others" include Printing and Publishing of Maps and Atlases.
3. The segment-wise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment.
4. The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED



Place : Chennai
Date : February 09, 2022

T T RAGHUNATHAN
Executive Vice Chairman

**TTK HEALTHCARE LIMITED**

Regd. Office : No.6, Cathedral Road, Chennai 600 086

CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND PERIOD ENDED 31ST DECEMBER, 2021

(Rs. in lakhs)

Sl. No.	Particulars	For the Quarter ended			For the period ended		For the year ended
		(31/12/2021)	(30/09/2021)	(31/12/2020)	(31/12/2021)	(31/12/2020)	(31/03/2021)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Total income from Operations	21,249.43	20,635.55	17,918.97	58,964.10	45,525.27	63,652.79
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items)	1,677.41	1,500.64	1,062.46	4,027.27	1,488.41	2,895.40
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary Items) [Refer Note No.6 below]	1,677.41	1,749.69	1,062.46	4,276.32	2,298.20	3,705.19
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items) [Refer Note No.6 below]	1,216.48	1,280.81	768.66	3,096.87	3,609.31	4,644.11
5.	Total comprehensive Income for the period [Comprising Profit / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax)]	1,375.89	1,211.29	784.22	3,528.02	3,858.13	4,989.26
6.	Equity Share Capital (Face Value of Rs.10/- per share)	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03	1,413.03
7.	Other Equity as per Balance Sheet of previous accounting year (excluding Revaluation Reserve)	-	-	-	-	-	27,610.18
8.	Earnings per share (of Rs.10/- each) (for continuing and discontinued operations)						
	(a) Basic (in Rs.)	8.61	9.07	5.44	21.92	25.54	32.87
	(b) Diluted (in Rs.)	8.61	9.07	5.44	21.92	25.54	32.87

Notes:

- The above is an extract of the detailed Statement of Unaudited Financial Results for the Third Quarter and Period ended 31st December, 2021, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The full financial results for the Third Quarter and Period ended 31st December, 2021 are available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).
- These financial results have been reviewed by the Audit Committee at its meeting held on 8th February, 2022 and approved by the Board of Directors of the Company at its meeting held on 9th February, 2022 through Video Conferencing.
- The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The second wave of CoVID-19 and the extended lockdown during the First Quarter of the Financial year 2021-22 has marginally impacted the business of the Company. Considering the ongoing vaccination drive and other sustainable actions taken by the Management, both with reference to the environment and its employees' health, the impact has been minimal.
The Company, based on current estimates, expects that the carrying amount of all its assets will be recovered, net of provisions established. However, the impact assessment of CoVID-19 is a continuing process, given the uncertainties associated with its nature and duration. The Company will continue to monitor any material changes to future economic conditions.
- Exceptional Items relating to FY 2021-22: In September, 2021, the Company sold land admeasuring 4.595 acres held by it at Perungudi Village, Tirunelveli District, Tamilnadu on which the Company has earned a profit of Rs.249.05 lakhs.
 - Exceptional Items relating to FY 2020-21: The Company's claim in respect of tax benefits due to adjustment of unabsorbed losses and depreciation of the erstwhile TTK Protective Devices Limited and TSL Techno Services Limited which merged with the Company w.e.f. 1st April, 2012, (shown as Contingent Asset in earlier years), has been allowed. The Company has received the revised assessment orders in the previous FY 20-21 and the refund received is accounted as follows:
 - Rs.809.79 lakhs towards Interest on Tax Refund received is treated as Exceptional Income; and
 - Balance Refund received (net of provisions of Rs 999.74 lakhs considered necessary) of Rs.1,964.81 lakhs has been accounted as Tax Refund relating to earlier years.
- Implementation of the Code of Social Security 2020, which is likely to impact the contributions by the Company towards Provident Fund, Gratuity and other related areas has been deferred by the Government beyond 1st April, 2021. However, the Company based on the initial assessment made a provision for Rs.350 Lakhs in the Fourth Quarter of FY 20-21 and proposes to take further appropriate action after the Rules are made applicable.
- The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED

T T RAGHUNATHAN
Executive Vice ChairmanPlace : Chennai
Date : February 09, 2022

PKF SRIDHAR & SANTHANAM LLP

Chartered Accountants

Independent Auditor's Review Report on review of Interim financial results

To the Board of Directors of TTK Healthcare Limited

We have reviewed the accompanying Statement of Unaudited financial results ("the Statement") of TTK Healthcare Limited ("the Company") for the quarter and period ended 31st December 2021. The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Listing obligations) which has been initiated by us for identification purposes.

Management's Responsibility

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

Auditor's Responsibility

Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **PKF Sridhar & Santhanam LLP**

Chartered Accountants

Firm's Registration No. 003990S/S200018



Aparna Jayendran

Partner

Membership No. 211692

Place: Chennai

Date: 09th February, 2022

UDIN No: 22211692AAYHWU8081